Perimeter Medical Imaging AI Unveils Financial Highlights for 2024
Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) recently reported substantial financial results for the fourth quarter and full year of 2024. This announcement highlighted the company’s strong momentum in the medical technology sector. They provided insights into their financial performance and also shared noteworthy updates about their operations and product advancements.
Impressive Business Growth and Development
Perimeter is making significant strides in the market, particularly with its first U.S. FDA-cleared product, the Perimeter S-Series OCT. In 2024, the company successfully placed nine S-Series OCT systems, a substantial increase from just three placements in 2023. Furthermore, the revenue generated in Q4-2024 saw an astonishing increase of 303% compared to the same period the previous year.
Technological Innovation and Expansion
The company is not only focusing on its existing products but is also advancing a new generation of imaging solutions. The Perimeter B-Series OCT system, which integrates proprietary AI technology, is in development and aims toward potential market introduction. This next-generation technology promises enhanced capabilities for aiding surgical procedures.
Pivotal Trials and Regulatory Progress
In late 2024, Perimeter reported key outcomes from pivotal studies meant to support their Premarket Approval (PMA) application to the FDA. The results from these studies indicated a statistically significant reduction in residual cancer detected during surgeries. Such positive outcomes underscore the effectiveness of the Perimeter B-Series in improving surgical margins, which can greatly reduce the likelihood of reoperations.
Financial Overview of 2024
During the fourth quarter of 2024, Perimeter reported revenues of approximately $293,000, resulting from consumables, system leases, and ESP warranty programs. The overall increase in revenue marks substantial growth and reflects the company's expanding market presence.
Operating Expenses and Financial Health
The company's operating expenses for the last quarter were approximately $4.7 million, showing a 6% decrease from the same quarter of 2023. Despite generating a net loss of about $3.4 million for the quarter, a notable 35% improvement over the previous year's loss indicates a positive trend in financial management.
Annual Performance Metrics
For the entire year, Perimeter achieved revenues of approximately $846,000, which is a significant 110% increase from $404,000 in the previous year. This growth is largely attributed to the increasing adoption of the S-Series OCT system across healthcare facilities. Operating expenses for the year rounded up to approximately $19.4 million, an increase from $16.7 million in 2023, marking a phase of intensive investment in growth and technology.
Corporate Updates and Future Projections
Perimeter continues to innovate and expand, as evidenced by its recent collaborations, including the introduction of the S-Series OCT technology in various hospitals. In March 2025, the company announced that the applications for the B-Series PMA have been submitted to the FDA, marking a significant milestone as it paves the way for broader applications of their pioneering technologies.
Strategic Vision
CEO Adrian Mendes expressed optimism regarding the company's trajectory, asserting that they are nearing a pivotal moment in their journey. With key trial results and regulatory submissions in place, the company stands poised for substantial growth, enhancing its mission of transforming cancer surgery through advanced imaging technology.
Frequently Asked Questions
What is Perimeter Medical Imaging AI known for?
Perimeter Medical Imaging AI specializes in advanced imaging technology for cancer surgery, primarily focusing on enhancing surgical precision.
How did Perimeter perform financially in 2024?
In 2024, Perimeter reported impressive revenue growth, achieving approximately $846,000, which marked a 110% increase over the previous year.
What products are highlighted in the report?
The report emphasizes the Perimeter S-Series and B-Series OCT systems, showcasing innovative technology for surgical applications.
What milestones has Perimeter achieved recently?
Perimeter has submitted a PMA application to the FDA for its B-Series, along with achieving significant commercial placements of the S-Series systems.
Who leads Perimeter's strategic direction?
Adrian Mendes serves as the CEO of Perimeter, steering the company toward its vision of improving surgical outcomes through groundbreaking technology.
